Please assess the completion status of the following clinical trial:

Trial Title: Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically proven Stage IV and Stage III (with malignant pleural or pericardial effusion) squamous or adenocarcinoma carcinomas of the lung~* Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis~* No previous anticancer treatment for metastatic/advanced disease. Patients who received prior adjuvant chemotherapy are eligible if they have remained free of disease for at least 6 months after the completion of adjuvant therapy.~* Age above 18 years~* Performance status (ECOG) 0-2~* Life expectancy \>= 3 months~* Effective contraception for both male and female subjects if the risk of conception exists~* Adequate hematologic parameters (absolute neutrophil count \>= 1.5x109/L and platelets \>= 100x109/L), creatinine (GFR\>= 60ml/min) and total bilirubin \< 1.5 times the upper limit of normal; aspartate and alanine aminotransferase \< 2,5 times the upper limit of normal~* All patients will have to sign written informed consent in order to participate in the study~Exclusion Criteria:~* Patients with non-squamous tumors who have no contradiction for administration of bevacizumab~* Active infection or malnutrition (loss of more than 20% of the body weight)~* Known hypersensitivity reaction to any of the component of the treatment~* Concurrent or previous chronic systemic immune therapy~* Pregnancy (absence to be confirmed by ß-HCG test) or lactation period~* Known alcohol/drug abuse~* Legal incapacity or limited legal capacity~* Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent~* A second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma~* Previous radiotherapy to the target lesions. Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields~* Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of uncontrolled arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Gemzar/Cisplatin
- 2 (Type: EXPERIMENTAL): Taxotere/Cisplatin
- 3 (Type: EXPERIMENTAL): Cisplatin/Navelbine metronomic
- 4 (Type: EXPERIMENTAL): Taxotere/Gemzar
- 5 (Type: EXPERIMENTAL): Gemzar
- 6 (Type: EXPERIMENTAL): Taxotere
- 7 (Type: EXPERIMENTAL): Navelbine metronomic
- 8 (Type: EXPERIMENTAL): Alimta/Cisplatin
- 9 (Type: EXPERIMENTAL): Alimta/Gemzar
- 10 (Type: EXPERIMENTAL): Taxotere
- 11 (Type: EXPERIMENTAL): Alimta

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues